Search - tctmd.com

Displaying 1 - 2 of 2

Sort: Relevancy | Date

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

March 29, 2025

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.